# The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain

> **NCT00212823** · PHASE4 · COMPLETED · sponsor: **Ortho-McNeil Neurologics, Inc.** · enrollment: 1450 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** almotriptan malate

## Key facts

- **NCT ID:** NCT00212823
- **Lead sponsor:** Ortho-McNeil Neurologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 1450 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00212823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00212823, "The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00212823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*